Small Molecule E1/E2 Inhibitors for HPV Recurrence Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for papilloma virus infections, such as genital verrucas, are inadequate as they do not completely remove viral particles and have high recurrence rates, with no specific antiviral treatments available targeting papilloma viruses like HPV.
Innovation Solution
Development of novel antiviral compounds that inhibit the replication of papilloma viruses by interfering with the interaction between the viral proteins E1 and E2, specifically designed to target low-risk HPVs like HPV6 and HPV11, formulated into pharmaceutical compositions for treatment and prevention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (physical destruction, cytotoxic agents, immuno-modulating agents) are used for genital verrucas, then some viral particles are removed, but recurrence rates remain high and secondary effects occur
Solution Approach 1:
The patent introduces small molecule compounds as intermediaries that specifically bind to and inhibit the E1/E2 protein-protein interaction interface. These compounds act as mediators that block the viral replication machinery without requiring physical destruction or cytotoxic effects, thereby reducing recurrence while minimizing secondary harmful effects.
Solution Approach 2:
The invention changes the fundamental parameter of treatment mechanism from physical/cytotoxic approaches to molecular inhibition. By targeting the specific biochemical interaction between E1 and E2 proteins, the treatment achieves more reliable viral particle removal with lower recurrence rates, as it addresses the root cause of replication rather than just symptoms.
2Adaptability or versatility
If no specific antiviral treatment targeting papilloma viruses is available, then current treatments can be applied, but they do not completely remove viral particles
Solution Approach 1:
The patent develops small molecule compounds that serve as specific intermediaries targeting the papilloma virus replication process. These compounds bind to the E1/E2 interaction interface, preventing viral genome replication and ensuring more complete removal of viral particles, thereby improving reliability while maintaining treatment versatility.
Solution Approach 2:
The invention replaces mechanical/physical treatment methods (cryotherapy, laser, surgical excision) with a biochemical mechanism - small molecule inhibition of protein-protein interaction. This substitution enables complete viral particle removal by targeting the replication process at the molecular level, rather than relying on physical destruction that may leave residual viral particles.
3Object-generated harmful factors
If physical destruction methods (cryotherapy, CO2 laser, electro-surgery) are used, then viral particles are destroyed, but significant recurrence rates are observed
Solution Approach 1:
The patent introduces small molecule compounds as specific intermediaries that block the E1/E2 protein interaction required for viral replication. This approach achieves viral particle destruction through biochemical inhibition rather than physical destruction, preventing recurrence by stopping the replication cycle at its molecular origin while maintaining reliable viral clearance.
Solution Approach 2:
The invention substitutes mechanical destruction methods (cryotherapy, laser, electro-surgery) with a biochemical mechanism - small molecule inhibition of the E1/E2 interaction. This replacement achieves more reliable recurrence prevention by targeting the fundamental replication process, ensuring complete viral particle removal without the high recurrence rates associated with physical methods.
4Reliability
If cytotoxic agents (TCA, podophyllin, podofilox) are applied, then viral particles are eliminated, but serious secondary effects occur
Solution Approach 1:
The patent employs small molecule compounds as specific intermediaries that selectively inhibit the E1/E2 protein interaction in papilloma viruses. This targeted approach eliminates viral particles reliably while minimizing secondary effects, as the compounds specifically bind to the viral protein interface rather than causing non-specific cytotoxic damage to surrounding healthy tissue.
Solution Approach 2:
The invention changes the treatment parameter from non-specific cytotoxicity to specific molecular inhibition. By targeting the precise biochemical interaction between E1 and E2 proteins, the treatment achieves reliable viral elimination while reducing harmful secondary effects through selective action on the viral replication machinery rather than general tissue damage.
Data Source
AI summary
HPV inhibitors of formula (I) in which G1 is —NHCO(CH2)n-, where n is an integer between 1 and 4, R3 is —CW(CH2)m—NR4R5 or —CW(CH2)mCH3 or —CN, where W is O, S or NH and m is an integer between 0 and 5, or R3 is one of the following groups: and A is an optionally substituted aryl group and B is an aryl group, preferably a phenyl which is substituted.